Intra-Cellular Therapies Inc. - ITCI STOCK NEWS

Intra-Cellular Therapies (Nasdaq: ITCI) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 11:15 a.m. PT, according to a recent announcement. The presentation will be led by Sharon Mates, Ph.D., CEO and Chairman of the company. Interested attendees can access the live and archived webcast on the company's Investor Relations webpage. Intra-Cellular Therapies focuses on developing innovative treatments for central nervous system disorders, based on Nobel prize-winning research.

Intra-Cellular Therapies (Nasdaq: ITCI) presented new findings at the ACNP 61st Annual Meeting, showcasing the efficacy and safety of CAPLYTA (lumateperone) for treating bipolar I and II depression. The analysis involved over 1,200 patients, confirming CAPLYTA's favorable cardiometabolic profile with no significant weight gain. Efficacy results indicated significant improvement in depression symptoms compared to placebo. Additionally, CAPLYTA demonstrated a low incidence of treatment-emergent mania and extrapyramidal symptoms. CAPLYTA is approved for schizophrenia and bipolar depression treatment.

Intra-Cellular Therapies (Nasdaq: ITCI) will participate in two investor conferences, aimed at advancing its focus on treatments for central nervous system disorders. The J.P. Morgan Equity Opportunities Forum takes place from November 14-15, 2022, in Miami, FL. Following this, the company will be featured at the Evercore ISI 5th Annual HealthCONx Virtual Conference on November 29, 2022, at 12:35 PM ET. Interested investors can access a live webcast of the fireside chat by visiting the company's website.

Intra-Cellular Therapies reported net product revenues of $71.9 million for Q3 2022, a 233% increase from Q3 2021. Total revenues rose to $71.9 million from $22.2 million year-on-year. While total prescriptions for CAPLYTA surged 220% year-over-year, net loss narrowed to $53.5 million compared to $76.9 million in Q3 2021. Cash reserves stood at $630.5 million as of September 30, 2022, bolstered by a $460 million public offering in January 2022. CAPLYTA's expansion into bipolar depression is ongoing, supported by new dosage strengths.

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) will hold a conference call on November 3, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ending September 30, 2022. This call aims to provide a corporate update and invite stakeholders to participate via a registration link. Interested parties can access the live and archived webcast through the Investor Relations section of the company's website. Intra-Cellular Therapies specializes in developing treatments for central nervous system disorders, leveraging innovative insights from cellular research.

Intra-Cellular Therapies reported a significant revenue growth of 178% in total revenues for Q2 2022, reaching $55.6 million, up from $20.0 million in Q2 2021. CAPLYTA net product revenues were $55.1 million, a 190% increase year-over-year and 58% over Q1 2022. Key metrics include a 225% rise in new prescriptions compared to Q2 2021. However, net loss escalated to $86.6 million from $68.7 million in the prior year. Cash reserves stood at $679.2 million as of June 30, 2022.

Intra-Cellular Therapies (Nasdaq: ITCI) announced a conference call on August 9, 2022, at 8:30 a.m. ET to discuss the financial results for Q2 2022 and provide a corporate update. Interested parties can join the call by dialing 1-(877) 407-8291 or accessing the webcast on the company's website. Intra-Cellular Therapies focuses on developing therapeutics for CNS disorders, utilizing innovative research to create solutions for complex psychiatric and neurologic diseases.

Intra-Cellular Therapies (ITCI) has presented new data regarding lumateperone (CAPLYTA) at the 2022 ISBD virtual conference. Key highlights include efficacy findings from Study 404, demonstrating significant improvements in depression scores (MADRS) and quality of life metrics in patients with bipolar depression. Lumateperone's favorable metabolic profile was also emphasized, showing stabilization of metabolic syndrome rates compared to placebo. Dr. Suresh Durgam expressed satisfaction with the positive feedback from the medical community regarding the drug's efficacy and safety.

Intra-Cellular Therapies reported strong first-quarter 2022 results, highlighting a 120% revenue increase to $35 million compared to Q1 2021. CAPLYTA (lumateperone) saw a remarkable prescription growth, with new prescriptions up 300% post-approval for bipolar depression, and total prescriptions rising 63% from Q4 2021. Net product revenues for CAPLYTA reached $34.8 million, a 123% year-over-year increase. However, a net loss of $72.1 million was reported, up from $52.7 million in the prior year, alongside escalating R&D and SG&A expenses.